LIVE

NRIX

Nurix Therapeutics, Inc.

NRIX

NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B

$23.97

▲ +0.25%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$8.20 - $24.88

P/E

-7.59

Fwd P/E

-10.04

Beta

1.87

Div Yield

0.00%

Avg Vol

2.0M

Shares Out

86.7M

Mkt Cap

$2.1B

Price action

Price chart

Up 92.2% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary protein degradation platform enabling selective target elimination
  • Strategic partnerships with Gilead Sciences and Sanofi providing validation and resources
  • Oral bioavailability of lead candidates improving patient accessibility
  • Differentiated approach to immuno-oncology through CBL-B inhibition
▼

Bear Case

1 risk

  • Above-average volatility (beta 1.9).

Growth

Moderate growth ahead

Clinical advancement of BTK degraders in relapsed/refractory B-cell malignancies

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+54.2% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 6, 2026

“
Q2 26 RECAP

APR 8, 2026

Reported EPS of -$0.79 vs -$0.76 consensus (-4.0% surprise). Revenue of $6.3M vs $14.3M expected (-56.1%).

EPS miss
Revenue miss

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-4.0%

Next: Apr 6, 2026

Revenue trend · last 8Q

—

—

-12%

+11%

+264%

-37%

+2%

-66%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$12.1M

$12.6M

$13.3M

$18.5M

$44.1M

$7.9M

$13.6M

$6.3M

Margins · last 8Q

Gross

—

Operating

—

Profit

-1394.3%

View full earnings history →

Wall Street consensus

9 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

9

100%

Hold

0%

Sell

0%

Median Price Target

$28.00

▲ +16.8% vs $23.97

Low $28.00
Median $28.00
High $28.00

Latest: HC Wainwright · Jun 11, 2026

1 analyst covering

View full analyst page →

vs Industry

How NRIX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.